A total of 1653 patients enrolled in the PROTECT trial who were discharged alive and with available blood samples were included. Forty-seven biomarkers were serially evaluated in these patients. Measurement closest to discharge was used to evaluate the predictive value of biomarkers for low and high post-discharge risk. Patients were classified as 'low risk' if post-discharge 30-day risk of death or heart failure rehospitalization was <5% while risk >20% was used to define 'high risk'. Cut-off values that yielded a 95% negative predictive value and a 20% positive predictive value were identified for each biomarker. Partial area under the receiver operating characteristic curve (pAUC) in the high-sensitivity and high-specificity regions was calculated to compare low-risk and high-risk predictive values. Of patients analysed, 193 (11.7%) patients reached the 30-day death or heart failure rehospitalization outcome. We found marked differences between low-risk and high-risk predictors. Cardiac-specific troponin I was the strongest biomarker for low-risk prediction (pAUC = 0.552, 95% confidence interval 0.52-0.58) while endothelin-1 showed better performance for high-risk prediction (pAUC = 0.560, 95% confidence interval 0.53-0.59). Several biomarkers (individually and in combination) provided added predictive value, on top of a clinical model, in both low-risk and high-risk regions.
Introduction
Nearly 20% of patients discharged after hospitalization for acute heart failure (AHF) need readmission within 30 days. short-term post-hospital discharge mortality is also at an unacceptably high level. In addition to significantly reducing survival and quality of life, the high rates of these post-discharge events (particularly readmissions) contribute substantially to the monetary cost of healthcare for heart failure (HF) patients. The total cost of HF care was estimated to be $31 billion in the USA alone in 2012 and this is projected to increase to an unprecedented $70 billion in 2030. 2, 3 The majority of this cost is associated with rehospitalizations. Several strategies have been proposed to reduce the enormous burden of early post-discharge events on patients and health care systems. 4 -9 Several observational data suggested that longer hospital stay and intensified post-discharge care are among the strategies that can be potentially beneficial in terms of lowering 30-day readmission rates.
10 -12 Nevertheless, such strategies are very unlikely to benefit the whole spectrum of hospitalized AHF patients and do not appear to be feasible, particularly from a cost-effectiveness perspective. A targeted approach in which low-risk patients are discharged early with less aggressive post-discharge monitoring while an extended, intensive in-hospital and post-discharge care is implemented in high-risk patients is a more feasible, and potentially cost-effective, strategy. Effective implementation of this strategy requires tools that can accurately identify subpopulations of patients at low or high risk of early post-discharge events. Nonetheless, prediction of these events, hospital readmissions in particular, remains a significant clinical challenge.
1,4,13
Biomarkers can play an essential role as objective tools for short-term post-discharge risk stratification in hospitalized AHF patients and, interestingly, several promising prognostic biomarkers are available. Traditionally, global measures of model performance such as the C-statistic have been used to quantify prognostic performance of biomarkers in prognostic AHF research.
14 -18 However, these parameters do not provide clear indication of the performance of biomarkers in certain risk ranges deemed to be clinically relevant, such as the low-or high-risk regions. There is evidence, particularly in diagnostic medicine, suggesting that the performance of biomarkers might significantly differ in specific clinically relevant regions of the receiver operating characteristic (ROC) curve, such as the rule-out (high sensitivity) or rule-in (high specificity) regions. 19 Subsequently, different sets of biomarkers might need to be used for more optimal identification of low-risk vs. high-risk subpopulations of patients. However, there is a limited objective data on the value of biomarkers for the identification of hospitalized AHF patients who are at low or high risk for post-discharge events. 20 In this exploratory study, we aimed to assess the value of biomarkers measured close to discharge for the identification of AHF patients at low and high risk for short-term post-hospital discharge events.
Methods

Study population
Data from the Placebo-controlled Randomized Study of the Selective A1 Adenosine Receptor Antagonist Rolofylline for Patients Hospitalized with Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function (PROTECT) trial were used in the present study. The PROTECT trial enrolled 2033 hospitalized AHF patients with a history of HF.
with BNP ≥500 pg/mL or N-terminal pro-brain natriuretic peptide (NT-proBNP) ≥2000 pg/mL and mild to moderate renal impairment were included in the trial. Details of the design and main results of the study have been published previously. 21, 22 All patients provided written informed consent. The study was conducted in compliance with the Declaration of Helsinki and was approved by all relevant local ethics committees. Patients who were documented to have been discharged from the index hospitalization alive were considered for inclusion in the present study (n = 1911).
Study procedures and measurements
Forty-three established and novel circulating biomarkers were evaluated at baseline and then daily until day 6 or discharge (whichever came first), day 7, and day 14. Measurement closest to discharge was used to define pre-discharge biomarker value. Albumin, alanine transaminase, aspartate transaminase, bicarbonate, blood urea nitrogen (BUN), chloride, creatinine, glucose, haemoglobin, platelet count, potassium, red blood cell count, sodium, total cholesterol, triglycerides, uric acid, and white blood cell count were measured in a central laboratory (ICON Laboratories, Farmingdale, NY, USA). A panel of 26 novel biomarkers was measured by Alere Inc. (San Diego, CA, USA) in available frozen serum samples. Galectin-3, myeloperoxidase and neutrophil gelatinase-associated lipocalin were measured using sandwich enzyme-linked immunosorbent assays (ELISA) on a microtitre plate; angiogenin and C-reactive protein (CRP) were measured using competitive ELISAs on a Luminex ® platform (Alere Inc., San Diego, CA, USA); D-dimer, endothelial cell-selective adhesion molecule, growth differentiation factor 15 (GDF-15), lymphotoxin beta receptor, mesothelin, neuropilin, N-terminal pro C-type natriuretic peptide, osteopontin, procalcitonin, pentraxin-3, periostin, polymeric immunoglobulin receptor, pro-adrenomedullin (proADM), prosaposin B, receptor for advanced glycation endproducts (RAGE), soluble ST-2 (sST-2), syndecan-1, tumour necrosis factor alpha receptor 1, Troy, vascular endothelial growth factor receptor 1 (VEGFR-1), and whey acidic proteins (WAP) four-disulphide core domain protein HE4 (WAP-4c) were measured using sandwich ELISAs on a Luminex ® platform (Alere Inc., San Diego, CA, USA). These research assays have not been standardized to the commercialized assays used in research or in clinical use and the extent to which each assay correlates with the commercial assay is not fully characterized. Four additional biomarkers-BNP, endothelin-1 (ET-1), interleukin-6 (IL-6) and cardiac-specific troponin I (cTnI)-were measured in frozen plasma samples collected at baseline and on days 2, 7, and 14 using high-sensitivity single molecule counting (SMC™) technology (RUO, Erenna ® Immunoassay System; Singulex Inc., Alameda, CA, USA). Details of assay information and the number of available measurements of each biomarker have been published previously. 24 A maximum difference of ±3 days was allowed between time of measurement and time of hospital discharge. Subsequently, patients discharged from hospital after 17 days of baseline assessment (n = 258) were excluded from the analysis by definition.
Study outcomes
Primary outcome evaluated in the present study was time-to-death or HF rehospitalization within 30 days of discharge. Time-to-all-cause mortality within 90 days of discharge was evaluated as a secondary outcome. Further sensitivity analysis was performed using time-to-death or rehospitalization for cardiovascular/renal causes by day 30 and time-to-all-cause mortality by day 180 (from index hospital admission).
Definitions
A threshold of 5% was considered an acceptable level of risk to categorize patients as 'low risk' for the 30-day risk of death or HF rehospitalization outcome. Subsequently, a cut-off value of a biomarker under consideration yielding negative predictive value (NPV) of 95% (i.e. corresponding to 5% false omission rate) was used to define low-risk status and, therefore, patients with biomarker values below this cut-off were classified as low risk. Conversely, a risk level of 20% for 30-day death or HF rehospitalization was used as the threshold defining 'high risk' status. In this case, a cut-off value of a biomarker yielding 20% positive predictive value (PPV) was employed to categorize patients as high risk. Patients with biomarker values above this cut-off were classified as positive for high risk. For secondary analysis with the 90-day all-cause mortality, risk thresholds of 2.5% and 15% were used to define low-risk and high-risk status, respectively.
Statistical analysis
Biomarker levels were summarized by 30-day death or HF rehospitalization status. Mean (SD) or median (interquartile range) was presented for normally and non-normally distributed continuous variables, respectively. Groups were compared with the independent t-test or Wilcoxon rank-sum test based on normality of distribution.
To define optimal cut-off values of biomarkers for the identification of low-risk and high-risk patients, time-dependent sensitivity and specificity with corresponding negative and positive predictive values were estimated at all possible cut-off values for each biomarker using R (R Foundation for Statistical Computing, Vienna, Austria) package survivalROC. A biomarker was considered to be predictive of low risk for 30-day death or HF rehospitalization if it had at least one cut-off value that reached a NPV of 95% or greater. Biomarkers fulfilling this criterion were then further evaluated in a comparative analysis. In this analysis, predictive performances were compared by estimating partial area under the ROC curve (pAUC) for each of the biomarkers considered to be predictive of low risk. The pAUC summarizes the discriminatory performance of a marker in a portion of the ROC curve defined based on a pre-specified sensitivity/specificity range of interest. 19 For the quantification of low-risk predictive value, the high sensitivity (i.e. rule-out) region of the ROC curve, defined as a sensitivity range from 0.9-1.0, was analysed. Patients with available measurements of all biomarkers considered to be predictive of low risk were included in this analysis. Evaluation of high-risk predictive value was performed by analysing pAUC in the high-specificity (i.e. rule-in) portion of the ROC curve, which was defined as a specificity range of 0.8-1.0. Patients with available measurements of all biomarkers considered to be predictive of high risk were included in this analysis. Here, a biomarker was considered predictive if it had at least one cut-off value reaching a PPV of 20% or greater. The R (R Foundation for Statistical Computing, Vienna, Austria) package pROC was used for the calculation of pAUC.
Biomarkers that had cut-off values that classified at least 10% of patients to either low risk or high risk (for the 30-day death or HF rehospitalization outcome) were then further analysed in multivariable analysis to quantify added predictive value in the rule-out or rule-in regions of the ROC curve on top of a clinical model. First, a clinical model encompassing baseline variables, including systolic blood
pressure, history of diabetes mellitus, atrial fibrillation, coronary artery bypass graft, hyperlipidaemia, past HF hospitalization, and diuretic response (defined as weight loss in kg per 40 mg of furosemide by day 4) was identified after implementation of a backward selection procedure on a logistic regression model that included candidate predictors associated with outcome at a significance level of 10%. A bootstrap analysis was incorporated in this procedure to ensure stability of model selection. In a second step, the added value of lowand high-risk predictive biomarkers in the rule-out and rule-in regions of the ROC curve, respectively, was quantified with the percentage change in pAUC attained with the addition of the biomarker under consideration to the clinical model. In this analysis, linear combination of biomarkers that maximizes the pAUC was identified based on the clinical model alone or clinical model plus biomarker and a linear predictor was calculated for each patient and this was entered as a marker for the calculation of pAUC. In a last step, the added value of a combination of biomarkers, on top of the clinical model, was evaluated by quantifying the gain the pAUC in the rule-out or rule-in regions. The combination of the smallest number of the top four best-performing biomarkers that yielded the highest pAUC in the respective risk regions was considered optimal.
A further analysis was performed at additional risk thresholds of 0%, 1%, 2%, 3%, and 4% for low risk and at risk thresholds of 22.5%, 25%, 27.5%, and 30% for high risk to determine cut-off values and associated proportion of patients that can be classified as low risk or high risk based on individual biomarkers, the clinical model, and clinical model plus combination of biomarkers.
Secondary analysis with the 90-day all-cause mortality outcome was performed applying the same procedure described above. Here, further analysis was performed at risk thresholds of 0%, 0.5%, 1%, 1.5%, and 2% for low risk and 17.5%, 20%, 22.5%, and 25% for high risk. A similar analysis was also performed using 30-day death or rehospitalization for cardiovascular/renal causes and time-to-all-cause mortality by day 180 after index hospital admission as sensitivity. A P-value <0.05 was considered statistically significant. Statistical analyses were performed with R: A Language and Environment for Statistical Computing, version 3.0.2 (R Foundation for Statistical Computing).
Results
Baseline clinical characteristics
Baseline clinical characteristics of patients included in the current analysis are presented in the Supplementary material online, Table S1 . Patients analysed were generally comparable to excluded patients (n = 258) in terms of baseline characteristics with the exceptions of small differences in degree of oedema, heart rate, body mass index, histories of angina, hypercholesterolaemia, and beta-blocker use. Outcomes were also comparable between the two groups (see the Supplementary material online, Table S2 ).
Discharge biomarker levels and outcomes
A summary of biomarker levels measured close to discharge by 30-day death or HF rehospitalization status is presented in Table 1 . A total of 193 (11.7%) and 129 (7.8%) patients reached the 30-day death or HF rehospitalization and 90-day all-cause mortality outcomes, respectively.
Low-risk prediction
Thirty-day death or heart failure rehospitalization
At a risk threshold of 5%, 13 biomarkers were found to be predictive of low risk. In a comparative analysis that included 1160 patients with available measurements of these 13 biomarkers, cTnI had the best predictive value with a pAUC = 0.552 and provided the greatest yield. At a cut-off value of 6.2 pg/mL, cTnI identified 251 (21.6%) patients with post-hospital discharge risk for 30-day death or HF rehospitalization below 5%. Syndecan-1, GDF-15, creatinine, and BNP showed a pAUC ≥0.53 in the rule-out region and had cut-off values that identified at least 10% of patients as low risk ( Table 2) .
Ninety-day all-cause mortality
A greater number of biomarkers (n = 19) were predictive of low risk for 90-day all-cause mortality. Among these, cTnI and IL-6 showed greater predictive value with a pAUC = 0.564. Interleukin-6, at a cut-off value of 6.0 pg/mL, identified 325 (28.0%) patients with post-discharge 90-day all-cause mortality risk below 2.5%, which was the greatest yield observed for this outcome. GDF-15, creatinine, and WAP-4c-identified at least 10% of patients as low risk for this outcome (see the Supplementary material online, Table S3 ).
High risk prediction
Eighteen biomarkers were predictive of high risk for 30-day death or HF rehospitalization at a risk threshold of 20%. A total of 1129 patients had available measurements of these biomarkers. ET-1 and procalcitonin showed the best predictive value in the rule-in region with a pAUC = 0.560. At a cut-off value of 7.0 pg/mL, ET-1 identified 306 (27.1%) of patients as high risk, which was the highest yield observed among biomarkers predictive of high risk. Procalcitonin, at a cut-off value of 0.04 ng/mL, categorized 265 (23.5%) patients as high risk for post-discharge 30-day death or HF rehospitalization. Six biomarkers-galectin-3, sST-2, RAGE, proADM, BUN, and VEGFR-1-also had cut-off values that identified at least 10% of patients as high risk ( Table 3) .
Ninety-day all-cause mortality
Fifteen biomarkers were predictive of high risk for 90-day all-cause mortality at a threshold of 15%. Among these sST-2, ET-1, and proADM had a pAUC = 0.60 in the rule-in region for 90-day all-cause mortality. The greatest yield was attained by sST-2 as it categorized 288 (25.5%) patients as high risk at a cut-off value of 5.0 ng/mL. Endothelin-1, IL-6, and procalcitonin, at cut-off values of 7.5 pg/mL, 20 pg/mL and 0.05 ng/mL, respectively, identified ∼20% of patients as high risk for 90-day all-cause mortality. Six additional biomarkers, including proADM, galectin-3, creatinine, VEGFR-1, BNP, and BUN, had cut-off values that categorized at least 10% of patients analysed as high risk (see the Supplementary material online, Table S4 ).
Added predictive value of individual and combination of biomarkers for low-risk prediction
The clinical model encompassing baseline systolic blood pressure, history of diabetes mellitus, atrial fibrillation, coronary artery bypass graft, hyperlipidaemia, prior HF hospitalization, and diuretic response had a pAUC of 0.628 and 0.625 for 30-day death/HF rehospitalization and 90-day all-cause mortality, respectively, in the low-risk region. Individual biomarkers provided modest incremental predictive value to the clinical model for the 30-day death/HF rehospitalization, as shown by the ∼1.0% gain in the pAUC attained with the additions of cTnI, creatinine, and BNP. Similarly, the gain attained with a combination of biomarkers was also limited for this endpoint. A combination of cTnI, creatinine, and BNP to the clinical model increased the pAUC to 0.652, only a 2.4% increment. The added value of biomarkers was more pronounced for the 90-day all-cause mortality. Both cTnI and IL-6 provided a 4.0% increment to the pAUC in the rule-out region. The addition of a combination of cTnI, IL-6, and BNP to the clinical model increased the pAUC to 0.718 (a marked 9.3% increment; 
Added predictive value of individual and combination of biomarkers for high-risk prediction
The clinical model had pAUCs of 0.618 and 0.570 for 30-day death/HF rehospitalization and 90-day all-cause mortality, respectively, in the high-risk region. Similar to low-risk prediction, the added value of biomarkers was very limited for the 30-day death/HF rehospitalization outcome in the high-risk region.
A combination of ET-1, sST-2, galectin-3, and BUN increased the pAUC to 0.634, which is only a 1.6% increment in the pAUC. In contrast, several biomarkers provided significant incremental predictive value for 90-day all-cause mortality. Individual additions of IL-6, proADM, BNP, BUN, and VEGFR-1 to the clinical model yielded >6.0% increment in the pAUC. Addition of a combination of ET-1, galectin-3, sST-2, and proADM to the clinical model increased the pAUC to 0.662, a 9.2% gain ( Table 5) . Figure 1 shows proportion of patients classified as low risk or high risk for the two outcomes at the different risk thresholds analysed for the three top-performing biomarkers (identified from the primary analysis), the clinical model and clinical model plus combination of biomarkers. For the 30-day death/HF rehospitalization outcome, cTnI remained the biomarker with the highest yield for low-risk prediction at all risk thresholds evaluated. However, the proportion of patients categorized as low risk decreased significantly with lower risk thresholds. The proportion of patients identified as low risk was <5% for risk thresholds below 3%. The yield was very low (<1.0%) for BNP and creatinine at all risk thresholds below 5%. For high-risk prediction, ET-1 provided the highest yield at risk thresholds of 22.5% and 25%. It classified ∼10-15% of patients as high risk at these thresholds. Nevertheless, all the three top-performing biomarkers for high-risk prediction provided very low yield at risk thresholds of 27.5% and 30%. However, the clinical model alone classified ∼15-20% of patients as either low risk or high risk at thresholds as low as 1.0% for low-risk prediction and as high as 30.0% for high-risk prediction. It must be noted that addition of combination of biomarkers to the clinical model did not add much compared with the yield of the clinical model alone (Figure 1) . For the 90-day all-cause mortality outcome, the yield attained with individual biomarkers was also significantly reduced at lower or higher risk thresholds for low-risk and high-risk prediction, respectively. Nonetheless, the model encompassing clinical variables and combination of biomarkers markedly increased the proportion of patients classified as either low risk or high risk at all risk thresholds. Even at a risk threshold of 0%, this model classified >20% of patients as low risk for 90-day all-cause mortality, while at a threshold of 25%, it classified >10% of patients as high risk for this outcome (Figure 1) .
Cut-off values and yields at other risk thresholds
Sensitivity analysis
As presented in the Supplementary material online, Tables S5 and S6, the best performing low-risk and high-risk predictive biomarkers for 30-day death or rehospitalization for cardiovascular/renal causes were generally comparable to that of the 30- 
Discussion
In this comparative study we evaluated the value of 47 established and novel biomarkers measured close to discharge for low and high post-discharge risk prediction in hospitalized AHF patients. We found a remarkable difference between those markers that showed good performance for the prediction of low risk and those that predicted high risk for two early post-discharge outcomes. For the 30-day death or HF rehospitalization outcome, cTnI provided the greatest performance for low-risk prediction while ET-1 and procalcitonin performed best for high-risk prediction. It was found that cTnI and IL-6 were the best-performing biomarkers for low-risk prediction using the 90-day all-cause mortality outcome while several biomarkers including ET-1, sST-2, and proADM showed good performance for high-risk prediction. Several biomarkers (both individually and in combination) provided added predictive value, on top of a clinical model, in both the low-risk and high-risk regions, which was more pronounced for the mortality outcome.
A demand-based approach that combines earlier discharge with less intensive post-discharge care in low-risk AHF patients and more extended and intensive in-hospital and post-discharge care in those at high risk is appealing as it might lead to improved outcomes. This strategy might also promote efficient distribution of scarce healthcare resources, potentially reducing the high 90-day all-cause mortality Figure 1 Size of low-risk (left) and high-risk (right) subpopulation of patients as a function of risk threshold for 30-day death or rehospitalization owing to heart failure (top) and 90-day all-cause mortality (bottom); results for top three biomarkers, clinical model and clinical model + combination of biomarkers are presented. BNP, B-type natriuretic peptide; cTnI, cardiac-specific troponin I; ET-1, endothelin-1; IL-6, interleukin-6; NPV, negative predictive value; PPV, positive predictive value; sST-2, soluble ST-2.
monetary cost associated with the care of HF patients. Development and effective implementation of such strategies requires tools that can accurately identify low-risk patients that can be safely discharged and treated less aggressively post-discharge and high-risk patients for whom more intensive in-hospital and post-discharge management is justified. Nevertheless, prediction of post-discharge events, particularly readmissions, with readily available clinical variables and standard laboratory parameters remains challenging.
1,4
Biomarkers can play an essential role in improving objective pre-discharge risk stratification and several promising prognostic biomarkers are currently available in AHF thanks to significant advances in proteomic research over recent years. 23 -27 However, there is a very limited data on the potential clinical utility of biomarkers for the identification of patients at low and high risk for short-term post-discharge complications.
The present study suggests that different sets of biomarkers need to be used for optimal low-and high-risk prediction.
. Interestingly, cTnI was the most promising biomarker for the identification of patients who are at low risk for post-discharge complications. This is consistent with a recently reported study by Pang et al., 28 which indicated that low levels of high sensitivity troponin T evaluated within 16 h of presentation could identify AHF patients at very low risk for cardiovascular mortality within 180 days of hospital admission. Although further investigation is required, the pivotal role of troponins in the management of acute coronary syndrome appears to have the potential to extend to the management of AHF patients. For high-risk prediction, ET-1 is, possibly, the most optimal individual biomarker as it showed consistently good performance for both outcomes evaluated. Endothelin-1 is a potent endogenous vasoconstrictor that had been indicated to have increased activity in HF through the upregulation of ET receptor A. 29 Perez et al. 30 evaluated the prognostic value of elevated ET-1 in hospitalized AHF patients included in the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF) trial. They showed that patients with baseline ET-1 levels in the highest tertile had the highest rate of 180-day all-cause mortality and, interestingly, risk persisted if ET-1 levels were maintained at the highest tertile after 48-72 h and 30 days of the baseline assessment. 30 Our findings further support the notion that persistence of ET-mediated vasoconstriction after in-hospital treatment could be an important marker of susceptibility to post-hospital discharge adverse outcomes. It must be emphasized that several other biomarkers reflecting diverse pathophysiological pathways also showed promising low-risk (e.g. IL-6, syndecan-1, GDF-15, BNP, BUN, and creatinine) and high-risk (e.g. procalcitonin, sST-2, galectin-3, IL-6, and proADM) prediction values. Plenty of biomarkers also provided added predictive value, on top of a clinical model, in both the low-and high-risk regions. Interestingly, both low-risk and high-risk prediction were further enhanced with combinations of biomarkers that encompassed markers reflecting the diverse pathophysiological pathways involved in HF.
The choice of outcome used to define risk did not show a significant effect on the selection of best-performing biomarkers for both low-risk and high-risk prediction. Except for small changes in ranking, biomarkers that showed good performance for the 30-day death or HF rehospitalization outcome also performed well for 90-day all-cause mortality. However, the inflammatory biomarkers (IL-6 in particular) are notable exceptions here. It was found that IL-6 was among the best predictors of both low and high risk for 90-day all-cause mortality yet it had poor performance for the 30-day composite outcome. This is not unexpected as we, in a post hoc analysis of biomarker data from the PROTECT trial, showed that IL-6 showed poor overall predictive value for 30-day death or rehospitalization for cardiovascular or renal causes despite having the highest C-index for both short and intermediate term all-cause mortality among 48 biomarkers evaluated. 24 Moreover, the added value of both individual and combinations of biomarkers, on top of the clinical model, was more pronounced for the 90-day all-cause mortality outcome. This, again, is consistent with our previous analysis, which showed that biomarkers are generally better at predicting mortality compared with rehospitalization outcomes, as quantified by overall predictive value.
Evaluation of performance of biomarkers in clinically relevant risk regions, as performed in the present study, is (probably) more important than the mere assessment of overall discriminatory accuracy for facilitating the clinical utility of the plethora of available prognostic biomarkers in AHF. However, defining these clinically relevant risk regions is a challenging task as the clinical and health economic implications of stratification into different risk categories remains unclear at this stage. Ideally, event rate should be close to zero in low-risk subpopulations of patients and significantly high enough to warrant more intensive treatment in high-risk subpopulations of patients. This must, however, be offset against the proportion of patients categorized as low or high risk for this risk stratification to have meaningful clinical impact. For the primary analysis of the present study, we used risk thresholds of 5% and 20% for 30-day death or HF rehospitalization to define low risk and high risk, respectively. At these thresholds ∼20-25% 
Strengths and limitations
We evaluated 47 established and novel biomarkers measured close to hospital discharge in a fairly large, well-characterized cohort of hospitalized AHF patients. However, the present study has several limitations. This is a post hoc analysis of data from a randomized controlled trial that was primarily designed to evaluate efficacy of rolofylline. Therefore, our analysis was exploratory and findings should only be considered as hypothesis generating. The PROTECT trial included a sicker subpopulation of AHF patients with significantly elevated natriuretic peptide levels, mild to moderate renal dysfunction, and previous history of hospitalization owing to HF during admission. Subsequently, extrapolation of our findings to the whole AHF patient population needs further evaluation. The importance of prospective validation of our findings should not be overstated at this point. Moreover, several of the biomarkers evaluated, in particular cTnI and BNP, were measured using assays that were not standardized to available commercial assays. Subsequently, cut-off values identified in the current analysis might not be generalized and need to be interpreted cautiously. Significant proportions of sST-2 and GDF-15 measurements available were at the lower and upper assay detection limits, respectively. This could potentially underestimate the performance of the two biomarkers for low (sST-2) and high (GDF-15) risk prediction.
Future steps
Currently, there appears to be a disconnect between disease severity and intensity of treatment in hospitalized AHF patients. An interesting analysis by Cotter et al. 10 that utilized data from the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS) trial showed that length of hospital stay was only partly explained by baseline disease severity. Another study by Davison et al., 31 utilizing data from the PROTECT trial, also showed a similar finding. We further explored whether several potential surrogates for physicians' judgment of disease severity [including total intravenous (i.v.) diuretic dose, length of hospital stay and i.v. inotrope/vasopressor administration] differed in groups of patients classified as low risk vs. high risk for post-discharge outcomes based on the most optimal discharge models we identified. As presented in the Supplementary material online, Table S9 , aside from a significant difference in total i.v. diuretic dose received through day 7 or discharge (if earlier), length of hospital stay and inotrope/vasopressor administration did not differ based on post-discharge risk of complications. These further support the assertion that objective risk stratification tools such as biomarkers are highly needed in AHF patients.
Although biomarkers could effectively identify low-and high-risk patients, there is a lack of guideline-recommended, risk-based interventions that could be implemented to reduce both the high rates of adverse outcomes and cost associated with hospitalization for AHF. This significantly limits the clinical application of risk stratification tools in general and biomarkers in particular. Thus, randomized controlled trials evaluating the effectiveness of targeted, risk-based interventions are needed in the future. Length of hospital stay is one area that might be of interest. There is some observational data suggesting that longer hospital stays might be beneficial, particularly in terms of reducing rates of readmissions.
10 -12 It will be interesting to evaluate the effectiveness and cost-effectiveness of an intervention that combines early discharge in low-risk patients and more extended in-hospital treatment in high-risk patients in a randomized controlled trial. Another potential target for intervention, particularly in high-risk patients, involves intensity of post-discharge care. Although available evidence is inconclusive, intensive monitoring strategies such as telemonitoring and natriuretic peptide-guided monitoring have been indicated as beneficial in some studies. 5 -8 It might be of particular interest to evaluate the effectiveness of such intensive monitoring strategies in a selected high-risk group of patients in a randomized controlled trial.
External validation of findings reported in the present study in an independent cohort of AHF patients is another essential step that is needed to facilitate the clinical applicability of the results. Last but not least, cost and availability of biomarker measurements is another important area that needs to be addressed in the future to facilitate the clinical utility of prognostic biomarkers. Quantification of cost-effectiveness of biomarker analysis, both individually and in tandem, is currently challenging as the clinical implications of information attained with prognostic biomarkers are still unclear. It could, however, be speculated that the advent of new technology that could enhance the speed and availability of biomarker measurements and reduce costs (e.g. point-of-care devices) will significantly enhance the clinical utility of biomarkers.
Conclusion
Different sets of biomarkers predict low risk vs. high risk of early post-discharge events in patients hospitalized for AHF. Therefore, this needs to be taken into consideration for optimizing biomarker-guided pre-discharge risk stratification strategies in hospitalized AHF patients. Further studies are needed to prospectively validate our observations in the general AHF patient population.
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